Isness: Using Multi-Person VR to Design Peak Mystical Type Experiences Comparable to Psychedelics
Open accessAbstract
Studies combining psychotherapy with psychedelic drugs (Ds) have demonstrated positive outcomes that are often associated with 'Ds' ability to induce 'mystical-type' experiences (MTEs) i.e., subjective experiences whose characteristics include a sense of connectedness, transcendence, and ineffability. We suggest that both PsiDs and virtual reality can be situated on a broader spectrum of psychedelic technologies. To test this hypothesis, we used concepts, methods, and analysis strategies from D research to design and evaluate 'Isness', a multi-person VR journey where participants experience the collective emergence, fluctuation, and dissipation of their bodies as energetic essences. A study (N=57) analyzing participant responses to a commonly used D experience questionnaire (MEQ30) indicates that Isness participants reported MTEs comparable to those reported in double-blind clinical studies after high doses of psilocybin and LSD. Within a supportive setting and conceptual framework, VR phenomenology can create the conditions for MTEs from which participants derive insight and meaning.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
VR can mimic the transcendental or mystical experiences produced by psychedelics, with promising results.
“Studies have been made regarding the potential of VR to mimic the transcendental or mystical experiences produced by psychedelics, with promising results (Glowacki et al., 2020)”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · cites this paper as Glowacki et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Using thematic analysis in psychology
Braun, V., & Clarke, V. (2006) · Qualitative Research in Psychology · doi:10.1191/1478088706qp063oa · Cited by 194,414 · see citing works
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 2× · see citing works
“The intervening years have seen a number of additional studies, where psilocybin has been administered to healthy volunteers; [24, 26] patients with life-threatening cancer diagnoses; [25, 67] people dealing with addiction; [18, 38, 39] and those afflicted with treatment-resistant depression [13].”
BackgroundNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762 · see citing works
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 4× · see citing works
“Double-blind trials [22, 23] and neuroimaging studies [7, 10] indicate that classical YDs hold strong potential as therapeutics for treating depression, addiction, and end-of-life anxiety associated with terminal illness.”
BackgroundInfluentialPilot study of the 5-HT <sub>2A</sub> R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · see citing works
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859 · see citing works
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Carhart-Harris, R. L., & Goodwin, G. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.84 · Cited by 706 · see citing works
Long-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696 · see citing works
Psychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657 · see citing works
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637 · see citing works
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506 · cited 5× · see citing works
“[40] Our attempts to understand whether the perceptual affordances of multi-person VR enable phenomenological experiences that create the conditions for MTEs which participants perceive as insightful and meaningful follows recent”
BackgroundInfluentialHartogsohn, I. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677852 · Cited by 483 · see citing works
Constructing drug effects: a history of set and setting
Hartogsohn, I. (2017) · Drug Science Policy and Law · doi:10.1177/2050324516683325 · Cited by 472 · see citing works
Psychiatry & the psychedelic drugs. Past, present & future
Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.040 · Cited by 343 · see citing works
Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates
Barrett, F. S., & Griffiths, R. R. (2017) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2017_474 · Cited by 273 · see citing works
The experimental use of psychedelic (LSD) psychotherapy.
Pahnke, W. N. (1970) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1970.03170240060010 · Cited by 220 · see citing works
LSD-Assisted Psychotherapy in Patients with Terminal Cancer
Grof, S., Goodman, L. E., Richards, W. A., & Kurland, A. A. (2017) · International Pharmacopsychiatry · doi:10.1159/000467984 · Cited by 209 · see citing works
Differential effects of MDMA and methylphenidate on social cognition
Schmid, Y., Hysek, C. M., Simmler, L. D., Crockett, M. J., Quednow, B. B., & Liechti, M. E. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114542454 · Cited by 155 · see citing works
Flagged first, then by citations
Research works printed but not linked: 15
- [3][3] Barsuglia, J., Davis, A. K., Palmer, R., Lancelotta, R., Windham-Herman, A.-M., Peterson, K., Polanco, M., Grant, R. and Griffiths, R. R. Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study. Front. Psychol. , 9, 2459 (2018). https://www.frontiersin.org/article/10.3389/fpsyg.2018.024 59 - · DOI
- [6][6] Carbonaro, T. M., Johnson, M. W., Hurwitz, E. and Griffiths, R. R. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology , 235, 2 (2018), 521-534. https://doi.org/10.1007/s00213-017-4769-4 - · DOI · Paper page
- [7][7] Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., Hobden, P., Evans, J., Feilding, 2. A., Wise, R. G. and Nutt, D. J. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A , 109, 6 (2012), 21382143. https://doi.org/10.1073/pnas.1119598109 - · DOI · Paper page
- [8][8] Carhart-Harris, R. L. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs (2014), 1-22. https://www.frontiersin.org/articles/10.3389/fnhum.2014.00 020/full - · DOI
- [9][9] Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A. and Nutt, D. J. LSD enhances suggestibility in healthy volunteers. Psychopharmacology , 232, 4 (2015), 785-794. https://doi.org/10.1007/s00213014-3714-z - · DOI
- [13][13] Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V. and Nutt, D. J. Psilocybin with psychological support for treatmentresistant depression: six-month follow-up. Psychopharmacology , 235 (2018), 399-408. https://doi.org/10.1007/s00213-017-4771-x - · DOI · Paper page
- [15][15] Chwelos, N., Blewett, D., Smith, C. and Hoffer, A. Use of d-lysergic acid diethylamide in the treatment of alcoholism. Quarterly journal of studies on alcohol , 20 (1959), 577-590. -
- [17][17] Eastman, P., Friedrichs, M. S., Chodera, J. D., Radmer, R. J., Bruns, C. M., Ku, J. P., Beauchamp, K. A., Lane, T. J., Wang, L.-P., Shukla, D., Tye, T., Houston, M., Stich, T., Klein, C., Shirts, M. R. and Pande, V. S. OpenMM 4: A Reusable, Extensible, Hardware Independent Library for High Performance Molecular Simulation. J. Chem. Theory Comput. , 9, 1 (2013), 461-469. http://dx.doi.org/10.1021/ct300857j - · DOI
- [18][18] Garcia-Romeu, A., R Griffiths, R. and W Johnson, M. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current drug abuse reviews , 7, 3 (2014), 157-164. https://doi.org/10.2174/1874473708666150107121331 - · DOI · Paper page
- [19][19] Glicksohn, J., Berkovich-Ohana, A., Mauro, F. and Ben-Soussan, T. D. Time Perception and the Experience of Time When Immersed in an Altered Sensory Environment. Frontiers in Human Neuroscience , 11, 487 (2017). https://www.frontiersin.org/article/10.3389/fnhum.2017.00 487 · DOI
- [20][20] Glowacki, B. R., Freire, R., Thomas, L. M., O'Connor, M. B., Jamieson-Binnie, A. and Glowacki, D. R. An open source Etextile VR glove for real-time manipulation of molecular simulations. arXiv:1901.03532 (2019). https://arxiv.org/abs/1901.03532 - · arXiv
- [21][21] Glowacki, D. R. Perceptions at the nanoscale. Nature Nanotechnology , 14, 5 (2019), 403-403. https://doi.org/10.1038/s41565-019-0452-8 - · DOI
- [23][23] Griffiths, R. R., Richards, W. A., Johnson, M. W., McCann, U. D. and Jesse, R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Psychopharmacology , 187, 3 (2008), 268-283. http://journals.sagepub.com/doi/10.1177/026988110809430 0 - · DOI
- [24][24] Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U. and Jesse, R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology , 218, 4 (2011), 649-665. https://doi.org/10.1007/s00213-011-23585 - · DOI
- [26][26] Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P. and Klinedinst, M. A. Psilocybinoccasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol , 32, 1 (2018), 49-69.
Cited by
Sorted by citations
Aday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237 · see citing works
Gómez-Busto, F. J., & Ortiz, M. I. (2020) · PubMed Central · doi:10.36131/cnfioritieditore20200606 · Cited by 12 · see citing works
- Authors
- Glowacki, D. R., Wonnacott, M. D., Freire, R., Glowacki, B. R., Gale, E. M., Pike, J. E., de Haan, T., Chatziapostolou, M., & Metatla, O.
- Affiliations
- University of Bristol (GB)
- Goldsmiths University of London (GB)
- ArtSci International Foundation, Bristol, United Kingdom
- Venue
- Proceedings of the 2020 CHI Conference on Human Factors in Computing Systems
- Publisher
- ACM
- Published
- 2020-04-21
- Pages
- 1-14
- OpenAlex
- W3003871080
- Cited by
- 54
- References
- 18
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 10 · 2023: 9 · 2022: 11 · 2021: 5 · 2020: 2
- FWCI
- 44.41
- Type
- conference paper
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- CHI Conference on Human Factors in Computing Systems (publishedVersion, cc-by-sa)
- Bristol Research (University of Bristol) (publishedVersion)
- arXiv (Cornell University) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- arXiv (Cornell University)
- Funders
- The Royal Society (URF/R/180033)
- Engineering and Physical Sciences Research Council (EP/P021123/1)
- Leverhulme Trust (Philip Leverhulme Award)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Physical Sciences › Computer Science › Human-Computer Interaction › Virtual Reality Applications and Impacts
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Keywords
- psychedelics, psychedelic-assisted psychotherapy, psilocybin, LSD, transcendence, ineffability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review